Table 1 Characteristics of children with JIA starting treatment with etanercept (N = 197) at baseline
Characteristics | All patients (n = 197) | Persistent oligoarticular | Extended oligoarticular | Polyarticular RF negative | Enthesitis-related |
|---|---|---|---|---|---|
(n = 84) | (n = 23) | (n = 64) | (n = 24) | ||
Female, n (%) | 137 (69.5) | 68 (81.0) | 16 (69.6) | 46 (71.9) | 5(20.8)d |
Age at JIA onset, median (IQR), years | 3 (2 – 7) | 2.3 (1.7 – 3.7)a | 2 (1.5 – 4) | 3.25 (2 – 7.5)a | 9 (5 – 11.8)d |
Age at start of etanercept, median (IQR), years | 7.25 (4 – 12) | 5.1 (2.9 – 8.9)a | 7.5 (3.5 – 10) | 9 (5.8 – 13)a | 13 (10.9 – 15.0)d |
Disease duration before start etanercept, median (IQR), years | 2.1 (1 – 5) | 1.9 (0.9 – 4)a | 3 (1.7 – 7) | 3.5 (1.8 – 6)a | 3 (1.5 – 5) |
History of chronic anterior uveitis, n (%) | 7 (3.6) | 3 (3.6) | 1 (4.3) | 3 (4.7) | 0 (0) |
History of at least 1 DMARD use except MTX, n (%) | 84 (42.6) | 24 (28.6)ab | 7 (30.4)c | 34 (53.1)a | 18 (75.0)bc |
History of at least 1 DMARD use, n (%) | 170 (86.3) | 69 (82.1) | 22 (95.7) | 57 (89.1) | 22 (91.7) |
History of ≥2 DMARDs use, n (%) | 76 (38.6) | 21 (25.0)ab | 6 (26.1) | 32 (50.0)a | 15 (62.5)b |
History of at least 1 biologic use, n (%) | 44 (22.3) | 10 (11.9)a | 5 (21.7) | 20 (31.3)a | 7 (29.2) |
History of ≥2 biologics use, n (%) | 7 (3.6) | 1 (1.2) | 0 (0) | 5 (7.8) | 1 (4.2) |
History of oral steroid use, n (%) | 55 (27.9) | 8 (9.5)ab | 7 (30.4) | 30 (46.9)a | 8 (33.3)b |
Concurrent MTX use, n (%) | 136 (69.0) | 51 (60.7)a | 21 (91.3)ab | 51 (79.7) | 12 (50.0)b |
Concurrent sulfasalazin use, n (%) | 6 (3.0) | 1 (1.2) | 0 (0) | 2 (3.1) | 3 (12.5) |
Concurrent oral steroid use, n (%) | 10 (5.1) | 0 (0) | 2 (8.7) | 5 (7.8) | 3 (12.5) |
NSAID use, n (%) | 121 (61.4) | 44 (52.4) | 15 (65.2) | 43 (67.2) | 18 (75.0) |